final brochure biotech japan 2015
TRANSCRIPT
Japan - IndiaA shared past - a glorious future India Pavilion @ BIOtech Japan 2015
Message
Dr. K. VijayRaghavanSecretary Department of Biotechnology Government of India
It gives the Department of Biotechnology -Government of India great pleasure to be present and exhibiting at BIOtech Japan 2015 and to have members of the Indian Biotechnology ecosystem from private and public sectors making the journey to Japan.Through history, Japan-India relations have traditionally been strong. For centuries, India and Japan have engaged in cultural exchange. Our two countries share a great tradition of scientific cooperation. Both countries are progressing well in various areas of Biotechnology and can surely benefit from each others’ strengths and expertise. With its large and skilled human resource base, India represents a large opportunity and market for any International organization for Research and Development as well as for innovative products. Japan with the world’s second largest pharmaceutical market represents a potential opportunity for Indian companies and public research institutes to cooperate.The government of both countries actively promote R&D and have many schemes for growing their industries. The Government of India has established the Biotechnology Industry Research Assistance Council (BIRAC) to support start-ups and other companies in their early stages. This has helped create a large number of companies that are at various stages of development. You will find several companies and organizations at the INDIA pavilion that are being encouraged by BIRAC. India has made a lot of progress in Agriculture through adoption of BT cotton and the government is supporting the development of safe use of biotechnology in Agriculture. Similarly India has come out with its Biosimilar Guidelines in 2012 and is also in the process of increasing clarity of its Clinical trials system. The Indian Parliament is considering a Biotechnology Regulatory Authority of India (BRAI) bill. We are optimistic that all these measures will help in increase the transparency and predictability of the regulations in India that will continue to spur the pace of the R&D efforts and encourage Local and Foreign investors.We wish to thank the BIOtech Japan 2015 organizers and various ministries of the Government of Japan and various associations for providing an opportunity for Indian exhibitors to showcase their strengths and to enable synergies with their Japanese counterparts.
Dr. K. VijayRaghavan
New Delhi, India
INDIAN BIOTECHNOLOGY : AN OVERVIEW
Dr. P.M. MuraliPresidentAssociation of Biotechnology Led Enterprises (ABLE)
INDUSTRY SEGMENTS The Indian biotechnology sector is presently divided into five segments of bio-pharmaceuticals, bio-services, bio-agriculture, bio-industrial and bio-informatics. Bio-pharma accounts for 63% of total revenues in the biotechnology sector, followed by bio-services at 19.2%, bio-agri at 13.3%, bio-industrials at 3.2% and bio-informatics at 1.2%. The breakup of individual sectors till 2012-13 is shown below and is similar for 2013-14.
MARKET OVERVIEW The biotechnology sector is one of the country’s major sectors. As per the Association of Biotechnology Led Enterprises (ABLE), the sector was estimated at around USD 4.8 billion in 2012. Overall the bioscience industry recorded a growth 25,165 crore in 2013-14. This was 7% growth over the previous year. India is amongst the top-12 biotech destinations in the world and ranks second in Asia, after China. It is also the largest producer of the recombinant Hepatitis B vaccine in the world.
Source : ABLE BIOSPECTRUM SURVEY, JULY - 2014
POLICY SUPPORT TO ACCELERATE GROWTH AND GOVERNMENT FUNDING
Strong Inflow of foreign investment and collaboration.
Colloborations and Acquisitions:
The Indian government has been proactive and supportive in driving the growth of the biotechnology sector by offering grants and tax incentives, and implementing investment-friendly regulations.
The government has taken several initiatives to promote the growth of the Indian biotechnology sector. Some of these are:
Advinus entered into a multiyear Drug Discovery collaboration with Takeda Pharmaceutical Company Limited focusing on novel targets for multiple Therapeutic Areas (October 2012). Some other deals since 2006 have been:
• Biotechnology Regulatory Authority of India: The Indian government has proposed the setting up of this authority by drafting the Biotechnology Regulatory Authority of India Bill, 2011. This authority is aimed to be set up as an independent body and legal committee to control the production, research, transport, import, and usage of organisms and products of modern biotechnology.
• Venture Fund: The Indian government has set up a USD 2.2 billion venture fund for supporting drug discovery and research infrastructure development projects. This is a crucial step as it increases the funding required for innovative work by the Indian biotech sector.
• Clinical Establishments Bill: The Indian government passed the Clinical Establishments Bill in the year 2010. This move is aimed at standardizing procedures for various clinical trial-related tasks.
• Make in India campaign launched in 2014.
• The Drugs & Cosmetics Act is currently being revised.
• Matrix Lab acquired by US-based Mylan Inc in August 2006
• Ranbaxy Laboratories acquired by Japan’s Daiichi Sankyo in June 2008
• Shantha Biotech took over by France-based Sanofi Aventis in July 2009
• Piramal Healthcare acquired by US-based Abbot Laboratories in May 2010
• Dabur Pharma acquired by Fresenius, Singapore
• Orchid Chemicals acquired by Hospira, US
• Ranbaxy acquired by Sun Pharma March 2015
ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES
Dr. P. M. MuraliPresidentEmail: [email protected]
Dr. Goutam DasChief Operating Officer
Email: [email protected]
Association of Biotechnology Led Enterprises (ABLE)No.123/C, 16th Main Road 4th Block, 5th Cross,Koramangala, Bangalore-560 034, India. Tel.: +91-80-41636853 Fax: +91-80-25633853
#09 Mercantile House,15 Kasturba Gandhi Marg,
New Delhi – 110 001, India.Telefax: +91-11-2373 1127
E-mail: [email protected] website:www.ableindia.in
ABLE – Association of Biotechnology Led Enterprises is a national forum that represents the Indian Biotechnology Sector. It was launched in April 2003 after industry leaders felt the need for an exclusive forum to represent the sector.
The primary objective of ABLE is to accelerate the pace of growth of the Biotechnology Industry in India, through partnering with the Government of India in their Biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaborations and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector. ABLE thus catalyses a symbiotic interface between the industry, the government, academic and research institutes and domestic and international investors.
Today, ABLE has approx.. 600 members representing all verticals of the sector like agribiotech, bio-pharma, industrial biotech, bioinformatics, investment banks and venture capital firms, leading research and academic institutes and law firms and equipment suppliers. ABLE works with all stake-holders, towards ensuring an effective, enabling and supportive environment for the Indian biotechnology sector to substantially contribute to India’s economic and social growth by providing access to affordable healthcare, food and clean and sustainable energy.
Mr. Sukesh Chandra GainSr. Manager, Business Development
Email: [email protected] Number: +91 80 2839 4015
Phone: +91 88 6111 8587
Mr. Lalit K. PawarVP & Head – Business Development
Email: [email protected] Number: +91 80 2839 4015
Phone: +91 973 170 1723
Advinus Profile:
Advinus Therapeutics Limited is a Drug Discovery and Development partner established in India with a specific objective of addressing productivity, timeline and ROI issues affecting the industry.
From the year 2006, its Drug Discovery Centre in Pune has generated a strong pipeline of 2 Phase II candidates, (1 being developed by a large partner and 1 internally) 4 candidates in pre-clinical development and multiple programs at varying stages of discovery. With the track record of bringing out of the box solutions for innovation and benchmark setting timelines, Advinus has distinction of being the first risk sharing partner for Merck, Novartis and J&J in India.
Since October 2012, Advinus has entered into a multiyear Drug Discovery collaboration with Takeda Pharmaceutical Company Limited focusing on novel targets for multiple Therapeutic Areas. Advinus has been receiving guaranteed research funding, and success based milestones with potential for royalties in future from this strategic discovery collaboration.
The Development Center, located in Bangalore, provides integrated pre-clinical and early clinical development services. Advinus has proven track record of submission of 29 successful INDs to regulatory agencies worldwide, all of which have received First in Human trial approval from regulatory agencies around the globe. Advinus has the largest vivarium in India (AAALAC certified) and is the only USFDA inspected GLP facility in India with no 483s (no major observations). The center has successfully executed over 6,000 Regulatory studies to agencies worldwide and completed 50 long-term rodent Carcinogenicity studies including those in Transgenic mouse model.
Advinus offers Pharmacol Toxicology, CMC services for IND and Lead Optimization services (DMPK and bioanalytical) under one roof. This enables us to deliver cost effective IND development in quick time within 6-9 months for less than a Million $.
Dr. Rashmi BarbhaiyaCEO and Managing DirectorAdvinus Therapeutics LimitedA TATA Enterprise21 & 22 Peenya Phase II, Peenya Industrial Area, Bangalore - 560 058 INDIATel : +91 80 2839 4959Fax : +91 80 2839 4015 E-mail : [email protected]
Dr. Shama Bhat, CMD [email protected]
11-A, 4th Cross, Veerasandra Industrial Area Electronics City, Bangalore 560100, Karnataka, India.
Profile:
Bhat Bio-tech India (P) Limited is specialized in the design development, manufacture and marketing of diagnostic products and Biotechnology based products. Diagnostic test devices are for various types of tests like, Pregnancy, HIV, Hepatitis, Malaria, Dengue, Chikungunya, Swine Flu (H1N1), Syphilis, TB, Cardiac Markers, Dry Chemistry, Bio-Chemistry, Hematology & Immunology and ELISA`S used in the analysis of body fluids in human. In Life Science related products we manufacture and market Genomics (DNA, RNA), Proteomics and Lab Instruments. Now, we would like to bring the molecular diagnostics to the point of care. State of the art Molecular Diagnostic kits, reagents and instruments are being developed and marketed. PCR Machines and I- PCR, the real time machine in less than 20 minutes are our recent inventions and will be launched shortly. We offer contract manufacturing, third party labeling, and contract research.
GLOBAL FOOTPRINTConsolidating its position as India’s niche and prominently acknowledged Diagnostic and Biotech Company, BBI has expanded operations to include several promising markets overseas effectively. Today, BBI exports to over 30 countries across the North America, UK, South Asia, Middle East, Central America, South America, South Africa and South East Asia.
Quality CERTIFICATIONSBBI is unflinchingly committed to continuous quality improvement and delivers products that strictly comply with stringent quality standards like ISO 9001, ISO 13485, CE Marking and Good Manufacturing Practices (GMP). All products are manufactured and tested under controlled and documented procedures, guaranteeing complete traceability and batch to batch uniformity. Hence, customers from across the world are assured of superior offerings that meet the most exacting quality demands.
RESEARCH AND DEVELOPMENT AT BHAT BIOTECHProduction of antigens in animal and E.coli cells are used for the production of kits for the detection of HIV, Malaria, Syphilis, etc. We have a group devoted to the development of monoclonal antibodies, FBA fragments and humanized antibodies. We also have initiated work on humanization of antibodies for eventual therapeutic applications as well as in the production of HVR fragments of antibodies in diagnosis. We have noted that on treatment of sera with proprietary agent proteins bands present only in the sera of patients infected with tuberculosis was visualized. This is the starting point of a multimodal multi-analyte immunochemical detection system that is being developed by us for the detection of tuberculosis. We also are developing the Impedance PCR system for the rapid detection of the bacteria in sputum. Finally we are initiating work for detection of MDR TB. We are developing fluorescently labeled probes (FISH) for the detection of Angelman’s , Phelan McDermid syndrome and other genetic disorders. We have a group that works on building instrumentation. We have built a PCR machine completely indigenously and are now developing an electrical method for the detection of DNA amplification measuring the Impedance of the PCR solution.. We are now working on developing an instrument for the measurement of glycated hemoglobin.
BHAT BIOTECH INDIA (P) LTD.
BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL
Dr. Renu SwarupSenior Adviser, Department of BiotechnologyMinistry of Science & Technology, Government of India &Managing Director, BIRAC1st Floor, MTNL Building, 9, CGO Complex, Lodhi RoadNew Delhi – 110 003, IndiaEmail: [email protected]: http://www.birac.nic.in
About BIRACEmpowering and Enabling the Biotech Innovation Ecosystem for affordable product development
Vision “To Stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry particularly SME’s, to make India globally competitive in biotech innovation and entrepreneurship, for creation of affordable products addressing the needs of the largest section of society.”
Key Strategies• Foster innovation and entrepreneurship in all places of research• Promote affordable innovation in key social sectors• Higher focus on start ups & small and medium enterprises• Contribute through partners for capability enhancement• Encourage diffusion of innovation through partners• Enable commercialization of discovery• Ensure global competitiveness of Indian enterprises.
Background Biotechnology Industry Research Assistance Council (BIRAC) was incorporated on 20th March 2012 as a PSU, ‘Not-for-Profit Company’ under the aegis of Department of Biotechnology, Ministry of Science & Technology, Government of India. BIRAC serves as a single window support for the emerging biotech industries. BIRAC is guided by an Independent Board of Directors comprising senior professionals, academicians, policy makers and industrialists.BIRAC is a new industry-academia interface and implements its mandate through a wide range of impact initiatives, be it providing access to risk capital through targeted funding, technology transfer, IP management and handholding schemes that help bring innovation excellence to the biotech firms and make them globally competitive. In its 3 years of existence, BIRAC has initiated several schemes, networks and platforms that help to bridge the existing gaps in the industry-academia Innovation research and facilitate novel, high quality affordable products development through cutting edge technologies. BIRAC has initiated partnerships with several national and global partners such as BMGF, Wellcome Trust, USAID and CEFIPRA to collaborate and deliver the salient features of its mandate.As a Government of India enterprise, it endeavors to bring professionalism, transparency and efficiency into its functioning while providing support to catalyze the transformation of the emerging Indian bio-economy.BIRAC envisages being a flexible and nimble organization that continues to play a catalytic and transformational role in building the Indian bio-economy and also being the bridge through which several stakeholders connect to bring innovative and affordable products into the market.
Some Statistics• 360 projects supported and mentored• More than 200 Start-ups and SME’s associated with BIRAC initiatives• Around 270 companies supported for innovation research funding• Supported 140 Scientists and Entrepreneurs• US $225 M contribution by BIRAC and Industry for Innovation research• Supported 15 bio-incubators to create 1,24,000 sq ft of incubation space • Started 5 University Innovation Clusters• Generated 24 IPs, supported development of 17 Affordable Products and 11 New Technologies
The Centre for Cellular and Molecular Platforms (C-CAMP) is a Department of Biotechnology (DBT, Govt. Of India) initiative and a member of the Bangalore Bio-Cluster (including NCBS and inStem). C-CAMP’s mandate is to enable successful bioscience research and entrepreneurship by making available cutting-edge technologies to life science researchers across India as well as providing hands-on training for scientists on these high-end technology platforms. Our technology platforms are Next Generation Genomics facility, Imaging Facility, Flow Cytometry, Mass Spectrometry facility, High Throughput Screening, Protein Technology Core, Transgenic Fly Facility, Microfluidics & Microfabrication facility and IP Management Office / Technology Transfer Office.
Technology Platforms: C-CAMP has till date reached out to and provided high-end platform technology services to more than 160 organizations across all our platforms and performed about 850 scientific studies, spanning over 8000 samples. With access to our high-end platforms and expertise of our platform directors and lab personnel, users have benefitted both in terms of high quality data and results as well as the opportunity to gain insight into their scientific questions.
NCBS-TIFR, GKVK Post, Bellary Road,Bangalore 560065, IndiaFax No: +91 80 2363 6662Telephone No: +91 80 67185100Email: ccamp@ ncbs. res.in
Centre for Cellular and Molecular Platforms (C-CAMP) NCBS-TIFR, GKVK Post, Bellary RoadBangalore 560065, India
Prof. Ramaswamy. S, Co-founder & CEO E-mail : [email protected]
Dr.Taslimarif Saiyed, Director and COOE-mail : [email protected] ;
CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS
Entrepreneurship: As a part C-CAMP’s mandate of promoting entrepreneurship and innovation, C-CAMP has created and fostered an entrepreneur-friendly culture in and around academic/research environment through its early translation accelerator program, which focuses on making early stage discoveries more industry and market ready; its involvement in seed funding schemes such as Biotechnology Ignition Grant (BIG) scheme from BIRAC, its Entrepreneur Mentorship program and its Bio-incubation facility. C-CAMP has partnered with BIRAC, DBT to help with the Biotechnology Ignition Grant (BIG) scheme grant that funds start-up companies and individual scientific entrepreneurs to establish proof-of-concept and transform these innovative ideas into viable competitive products and enterprises. Through the BIG Entrepreneur Mentorship program, C-CAMP not only funds but also nurtures these start-ups with scientific and business mentorship. C-CAMP’s involvement in the BIG scheme, has further expanded C-CAMP’s entrepreneurial activities to providing some of these start-ups access to functional laboratory along with high-end technology platforms, through bio-incubation. Today C-CAMP has funded (via BIRAC) and mentors around 45 life science start-ups/spin-offs, of which 10 are incubating at C-CAMP and leveraging the technology platforms and scientific expertise on campus.
VISION: “Attaining new heights in biotechnology research, shaping biotechnology into a premier precision tool of the future for creation of wealth and ensuring social justice - specially for the welfare of the poor”.
MISSION: • To launch a major well directed effort with significant investment, for harnessing biotechnological tools for generation of products, processes and technologies to enhance the efficiency and productivity and cost effectiveness of agriculture, nutritional security, molecular medicine, environmentally safe technologies for pollution abatement, biodiversity conservation and bio-industrial development.
• Scientific and technological empowerment of India’s incomparable human resource.
• Creation of a strong infrastructure both for research and commercialization, ensuring a steady flow of bio-products, bioprocesses and new biotechnologies.
Department of Biotechnology Ministry of Science & Technology, Government of India
CGO Complex Block-2, 6th – 8th Floor, New Delhi-110003 – IndiaTelephone No: 011-24362950 Web site: www.dbtindia.gov.in
Prof. K VijayRaghavanSecretaryThe Department of Biotechnology (DBT) was set up in 1986 with a
Today the DBT is recognized as a major national research and development agency in India, provid-ing nearly two-third of the R&D support in the life sciences sector. The department has been continuously promoting biotechnology in the country by paying attention on creating an institutional framework for biological science and biotechnology, human resources at Ph.D. and Post Doctoral level and nurturing sci-entific and technology community for advancement in their respective field. Indian scientists have done extremely well during the past years with several outstanding publications in prestigious and high impact journals. The performance of our university and academic institutions in this field has been excellent. The Indian biotech industry has grown at a fast pace to report revenues of US$ 4.3 billion in 2012-13, a rise of 15 per cent over the previous year, according to the eleventh annual survey conducted by the Association of Biotechnology-Led Enterprises (ABLE) and a monthly journal, BioSpectrum. The budgetary allocation of the department has increased from around 230 million INR in 1986-1987 to 15 billion INR in 2012-2013. Currently the Department has 15 autonomous institutions covering areas of plant, animal, human sciences and industrial biotechnology.
The Department received 1900 projects in the past year and has approved 667 projects. All the R&D projects received in the department are subjected to rigorous review mechanisms including internal screening, peer review and evaluation by various committees. Most of the projects are sanctioned in six to nine months. The department has implemented electronic Project Management and Information Sys-tem (eProMIS) and constantly trying to improve its functioning. The Department is implementing Result Framework Document (RFD) System of measuring performance of departments in various ministries of the Government since its inception at pilot scale in the last quarter (January-December) of financial year 2009-2010. During the financial year 2010-2011, the department was rated within the top three by the Performance Management Division (PMD) of Cabinet Secretariat in terms of accomplishing agreed objec-tives of the year. The targets, timelines and achievements as per the RFD format for the year 2011-2012 has been reviewed by the High Power Committee (HPC) on Government Performance. The HPC based on the data submitted by the department has approved a composite score of 89.72 for the year 2011-2012.
The Department has also setup BIRAC (Biotechnology industry Research Assistance Council) a not-for- profit company under Section 25 which serves as a single window for the emerging biotech industries. The impact of the biotechnology related developments in agriculture, health care, environment and in-dustry, has already been visible and the efforts are now culminating into products and processes. These results have led to more than 5000 research publications, 4000 post-doctoral students, several technolo-gies transferred to industries and patents filed including US patents. The DBT interacts with more than 5,000 scientists per year in order to utilize the existing expertise of the universities and other national laboratories. There has been close interaction with the State Governments particularly through State S & T Councils for developing biotechnology application projects, demonstration of proven technologies, and training of human resource in States and Union Territories. Necessary guidelines for transgenic plants, recombinant vaccines and drugs have also been evolved.
Ms. Tanusree Deb Barma, IASManaging Director- [email protected]
Karnataka referred to as the “Knowledge Hub of Asia”, is the leader State for Biotechnology in India, owing to its pioneering efforts towards devising several biotech policy initiatives to be in pace with the rapidly growing sector. KBITS formed under Karnataka Societies Registration Act in 2000 – 2001 assists the State in establishment of Bio Incubation Centers as part of the Biotech Parks in Bangalore, Mysore, Dharwad, Mangalore and Bidar cities; in promoting IT & BT sectors by organizing Trade shows, Conferences, Seminars held at National/ International levels; in projecting state’s potential for invest-ments, in assisting industries for clearances, incentives and concessions. KBITS supports enhancement of human resources in high caliber R&D institutions; and in building quality youth ready for employment by the biotech companies via the Biotechnology Finishing Schools program. KBITS works closely with the Department of Biotechnology – Government of India, ABLE (Association of Biotechnology Led Enterprises) and other stake holders to be in alignment with the national priorities. Below are a few of the major ini-tiatives triggered by KBITS:
Institute for Bioinformatics & Applied Biotechnology (IBAB): IBAB Conducts R&D in the area of Bioin-formatics and relevant areas; Offers Masters, Doctoral and Post-Doctoral programs; Provides short-term training programs; facilitates incubation (via Bangalore Bioinnovation Center- BBC) for entrepreneurs; Collaborates with scientists of high repute nationally and internationally.
Centre for Human Genetics (CHG): This is a centre of advanced research, teaching and training in areas which lie at the interface of modern genetics and medicine. Known for its high quality of genetic diagno-sis and counseling services, CHG has provided diagnostic and counseling services to over a 7000 fami-lies with genetic disorders. CHG conducts short-term courses in human disease genetics and molecular cytogenetics attracting young scientists and clinicians.
Institute of Agri Biotechnology (IABT): Set up in collaboration with University of Agricultural Sciences – Dharwad, the institute conducts innovative research to identify and integrate traits into crops for increas-ing agri-productivity. IABT offers Masters, Doctoral and Post-Doctoral Programs, facilitated incubation of entrepreneurs and provides services to farmers
Biotechnology Finishing School Program (BTFS): Established with the required course content and dura-tion to enhance graduates and post-graduates with the necessary employable skills for rapid acceptance by the biotech industry. In its 4th year BTFS program has become increasingly popular owing to a good fellowship support by DBT-GOI and high job placements.
Dr. Mittur N. Jagadish, PhDHead- Biotechnology Facilitation Cell
KBITS(KARNATAKA BIOTECHNOLOGY AND INFORMATION TECHNOLOGY SERVICES)DEPARTMENT OF IT BT AND S&T, GOVERNMENT OF KARNATAKA – BENGALURU
- KARNATAKA
ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES
ADVINUS THERAPEUTICS LIMITED
BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL
DEPARTMENT OF BIOTECHNOLOGY MINISTRY OF SCIENCE & TECHNOLOGY
CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS
BHAT BIOTECH INDIA (P) LTD.
KARNATAKA BIOTECHNOLOGY AND INFORMATION TECHNOLOGY SERVICESDEPARTMENT OF IT BT AND S&T, GOVERNMENT OF KARNATAKA
DEPARTMENT OF BIOTECHNOLOGY Ministry of Science & Technology, Government of India
CGO Complex Block-2, 6th – 8th Floor, New Delhi-110003 – IndiaTelephone No: 011-24362950 Web site: www.dbtindia.nic.in
BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL 1st Floor, MTNL Building, 9, CGO Complex, Lodhi Road, Next to Scope Complex,
In front of gate no. 13, J.L.N. Stadium), New Delhi – 110 003, India Tel: +91-11-24389600 Fax: +91-11-24389611
Email: [email protected]
EMBASSY OF INDIA Counsellor of Science & Technology
2-2-11 Kudan-Minami, Chiyoda-ku, Tokyo [email protected] Tel : +81 3 3262-2391 to 97
BANGALORE - No.123/C, 16th Main Road 4th Block, 5th Cross,Koramangala, Bangalore-560 034, India.
Tel.: +91-80-41636853 Fax: +91-80-25633853
NEW DELHI - #9, Mercantile House,15, Kasturba Gandhi Marg, New Delhi - 110001
Telefax +91-11-23731127Email: [email protected]
www.ableindia.in
Department of BiotechnologyMinistry of Science and Technology
Government of India
ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES (ABLE)
KARNATAKA BIOTECHNOLOGY & INFORMATION TECHNOLOGY SERVICES
BMTC- Central Offices Building, TTMC ‘B’ Block, 4th Floor, Shanthinagar, KH Road,
Bangalore 560 027Ph : 91-80-22231006 & Fax : 91-80-22231006
Website: www.bangaloreitbt.in & Email: [email protected]